Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 13Glioblastoma 10Glioma 7Astrocytoma 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasms 4Brain Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Melanoma 2Carcinoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Diseases 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Seroma 1Rectal Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Patient Preference 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × Surgical Procedures, Operative × Clear all
NCT03800134 2025-06-11

AEGEAN

AstraZeneca

Phase 3 Active not recruiting
825 enrolled 1 FDA
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00191308 2011-10-21

Molecular Profiling in Lung Cancer Patients

Eli Lilly and Company

Phase 2 Completed
30 enrolled 11 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡